Patent 11786524 was granted and assigned to Sentinel Oncology Limited on October, 2023 by the United States Patent and Trademark Office.
This invention relates to compounds that inhibit or modulate the activity of Chk-1 kinase. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.